Go to article: Home | Biosimilars set the stageGo to article: In this issueGo to article: ContentsGo to article: CSafeAPSGo to article: Mimotopes Company Insight Go to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: TripletreeGo to article: CommentGo to article: Cannabinoids receptors: popular preclinical target but banned in 137 countriesGo to article: Ozempic compensating for Wegovy’s supply shortage due to high demandGo to article: Manufacturing challenges set back progress of cell therapies in oncologyGo to article: Chinese transition to innovative pharma needs more investmentGo to article: DLBCL: a rapidly evolving treatment landscape with a crowded pipelineGo to article: Bio Image Systems Inc.Go to article: In DepthGo to article: Humira biosimilars set the stage for long-awaited 2023 US launchesGo to article: Expanding ketamine’s horizons for rare neurological disordersGo to article: The “Medical Bypass”: New drugs to strike obesityGo to article: Running low on comparators: drug shortages in oncology clinical trialsGo to article: ACT EU state of play: EMA’s headway to transform clinical trialsGo to article: CMO Moves: Regulatory catalysts for drug manufacturing-DecemberGo to article: EventsGo to article: Next issue